Ivor Elrifi Buys 667,000 Shares of Tiziana Life Sciences (NASDAQ:TLSA) Stock

Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi acquired 667,000 shares of the stock in a transaction dated Monday, August 3rd. The shares were bought at an average cost of $1.00 per share, with a total value of $667,000.00. Following the completion of the transaction, the chief executive officer owned 4,472,261 shares of the company’s stock, valued at approximately $4,472,261. This represents a 17.53% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Ivor Elrifi also recently made the following trade(s):

• On Wednesday, August 5th, Ivor Elrifi bought 237,616 shares of Tiziana Life Sciences stock. The shares were purchased at an average price of $1.00 per share, for a total transaction of $237,616.00.
• On Tuesday, August 4th, Ivor Elrifi bought 83,807 shares of Tiziana Life Sciences stock. The stock was purchased at an average cost of $0.97 per share, for a total transaction of $81,292.79.

Tiziana Life Sciences Trading Down 1.6%

Shares of Tiziana Life Sciences stock opened at $0.97 on Friday. Tiziana Life Sciences Ltd has a 52-week low of $0.87 and a 52-week high of $2.53. The company has a 50 day moving average of $1.14 and a 200 day moving average of $1.30.

Hedge Funds Weigh In On Tiziana Life Sciences

Several hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP raised its holdings in Tiziana Life Sciences by 5.2% during the fourth quarter. Marshall Wace LLP now owns 282,017 shares of the company’s stock worth $420,000 after purchasing an additional 14,005 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Tiziana Life Sciences in the 3rd quarter valued at $520,000. Jane Street Group LLC grew its position in shares of Tiziana Life Sciences by 968.2% in the 1st quarter. Jane Street Group LLC now owns 167,542 shares of the company’s stock valued at $181,000 after buying an additional 151,858 shares during the last quarter. Zhang Financial LLC grew its position in shares of Tiziana Life Sciences by 12.0% in the 1st quarter. Zhang Financial LLC now owns 111,900 shares of the company’s stock valued at $131,000 after buying an additional 12,000 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Tiziana Life Sciences by 413.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 110,290 shares of the company’s stock worth $164,000 after acquiring an additional 88,830 shares in the last quarter.

Analysts Set New Price Targets

Several research firms have recently issued reports on TLSA. Wall Street Zen cut shares of Tiziana Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Weiss Ratings lowered Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 29th. Finally, Zacks Research upgraded Tiziana Life Sciences to a “hold” rating in a research note on Tuesday, July 14th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Tiziana Life Sciences currently has a consensus rating of “Reduce”.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small?molecule program, milciclib, is an oral cyclin?dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.